Vismodegib
ATC L01XJ01 · 8 markets · 11 records
AU 3 records · 2 strengths
- 150 mgcapsuleERIVEDGEERIVEDGE vismodegib 150 mg hard capsule bottle
Records without a stated strength · 1 ERIVEDGE
CA 2 records · 1 strengths
- 150 mgcapsuleERIVEDGESPC-VISMODEGIB
US 1 records · 1 strengths
- 150 mgcapsuleERIVEDGE
GB 1 records · 1 strengths
- 150 mgcapsuleERIVEDGE
ES 1 records · 1 strengths
- 150 mgcapsuleERIVEDGE
TW 1 records · 1 strengths
- 150 mgcapsuleERIVEDGE愛維德膠囊150毫克
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 ERIVEDGE
| Strength / form / release | US | GB | CA | AU | ES | TW | EU |
|---|---|---|---|---|---|---|---|
| 150 mg capsule | ERIVEDGE | ERIVEDGE | ERIVEDGE SPC-VISMODEGIB | ERIVEDGE ERIVEDGE vismodegib 150 mg hard capsule bottle | ERIVEDGE | ERIVEDGE 愛維德膠囊150毫克 | |
unknown | ERIVEDGE | ERIVEDGE |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.